EntreMed spins off cell permeation technology company
This article was originally published in Clinica
Executive Summary
EntreMed, a US drugs company working on antiangiogenesis compounds, is putting its drug and gene delivery technology into a separate company. TheraMed will commercialise its proprietary cell permeation technology using flow electroporation.